FRENCH ORGANOIDS & ORGANS-ON-CHIP INITIATIVE (F3OCI).
NETRI AT THE HEART OF THE F3OCI INITIATIVE.
NETRI's active involvement in structuring the O&OoC sector confirms its role as a leader in innovative healthcare technologies. Thanks to its expertise and strategic partnerships, the company is helping to position France as a major player on the international organoids and organs-on-chip scene.
A strategic sector in full structuring.
Since 2023, France has taken a major step forward in the development of healthcare technologies by launching the Strategic Sector Contract (CSF) "Healthcare Industries and Technologies". This contract, signed at the Ministry of the Economy, Finance and Industrial and Digital Sovereignty, aims to structure and boost innovative sectors, including organoids and organs-on-chip (O&OoC). This promising field offers alternatives to animal models for preclinical and clinical research, thus meeting major ethical and scientific challenges.
NETRI, a key player in the initiative.
Based in Lyon, NETRI is an industrial start-up specializing in the design and production of organs-on-chip. Its microfluidic devices can reproduce the innervation and vascularization of any organ and human physiological functions in vitro, offering predictive models for drug development. As a representative of France Biotech, NETRI co-pilots the O&OoC working group within the CSF, alongside BioValley France. The aim of this collaboration is to federate industry players, promote O&OoC technologies and facilitate their integration into regulatory processes.
Concrete initiatives to structure the sector.
To support the development of the O&OoC sector, several actions have been implemented:
•Webinars and workshops: Regular events are organized to share technological advances, feedback and industry outlooks.
•Creation of a directory and a map: A list of players in the sector has been drawn up to facilitate collaboration and identify the expertise available in the region.
• Launch of the PEPR MED-OOC program: This €15 million research program aims to develop the next generation of organs-on-a-chip, focusing on the personalization of models and their integration into the care pathway.
Institutional and political recognition.
The commitment of NETRI and its partners has helped raise political awareness of the strategic importance of O&OoC technologies. The signature of the CSF and support for the PEPR MED-OOC program testify to the French government's determination to promote these innovations, in line with the objectives of the France 2030 plan. This recognition paves the way for better coordination of research efforts, harmonization of standards and greater visibility for the industry on the international stage.
Towards more ethical and personalized medicine.
Organoids and organs-on-chip represent a major advance for the medicine of the future. By reproducing the functions of human organs, they enable us to better understand disease mechanisms, test the efficacy and toxicity of drugs, and develop personalized therapeutic approaches. What's more, by reducing the need for animal experimentation, these technologies respond to growing ethical concerns.
